Cox regression analysis results for OS results
| . | Univariate HR (95% CI) . | P value . | Multivariate HR (95% CI) . | P value . |
|---|---|---|---|---|
| 5-6 bendamustine cycles (vs 3-4) | 0.75 (0.57-0.98) | .04 | 0.87 (0.66-1.15) | .33 |
| Age (per 5-y increase) | 1.46 (1.31-1.62) | <.01 | 1.40 (1.25-1.58) | <.01 |
| Female sex (vs male) | 0.61 (0.47-0.80) | <.01 | 0.63 (0.48-0.83) | <.01 |
| Previous cancer (vs no) | 1.60 (1.17-2.18) | <.01 | 1.37 (1.00-1.88) | .05 |
| Second primary malignancy (vs no) | 2.02 (1.48-2.75) | <.01 | 2.03 (1.49-2.78) | <.01 |
| NCI comorbidity index (per 1-unit increase) | 1.14 (1.07-1.21) | <.01 | 1.10 (1.03-1.18) | <.01 |
| Rituximab before bendamustine (vs no) | 1.48 (1.19-2.11) | <.01 | 1.36 (1.01-1.82) | .04 |
| Rituximab with bendamustine (vs no) | 0.41 (0.21-0.81) | <.01 | 0.46 (0.23-0.92) | .03 |
| Time from diagnosis to treatment start (per 6-mo increase) | 1.04 (1.01-1.06) | <.01 | 1.00 (0.98-1.03) | .80 |
| . | Univariate HR (95% CI) . | P value . | Multivariate HR (95% CI) . | P value . |
|---|---|---|---|---|
| 5-6 bendamustine cycles (vs 3-4) | 0.75 (0.57-0.98) | .04 | 0.87 (0.66-1.15) | .33 |
| Age (per 5-y increase) | 1.46 (1.31-1.62) | <.01 | 1.40 (1.25-1.58) | <.01 |
| Female sex (vs male) | 0.61 (0.47-0.80) | <.01 | 0.63 (0.48-0.83) | <.01 |
| Previous cancer (vs no) | 1.60 (1.17-2.18) | <.01 | 1.37 (1.00-1.88) | .05 |
| Second primary malignancy (vs no) | 2.02 (1.48-2.75) | <.01 | 2.03 (1.49-2.78) | <.01 |
| NCI comorbidity index (per 1-unit increase) | 1.14 (1.07-1.21) | <.01 | 1.10 (1.03-1.18) | <.01 |
| Rituximab before bendamustine (vs no) | 1.48 (1.19-2.11) | <.01 | 1.36 (1.01-1.82) | .04 |
| Rituximab with bendamustine (vs no) | 0.41 (0.21-0.81) | <.01 | 0.46 (0.23-0.92) | .03 |
| Time from diagnosis to treatment start (per 6-mo increase) | 1.04 (1.01-1.06) | <.01 | 1.00 (0.98-1.03) | .80 |